Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections | Zendy

Stanley I. Martin | Zendy; Goodman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections

Author(s) -

Stanley I. Martin,

Goodman

Publication year - 2012

Publication title -

therapeutics and clinical risk management

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.719

H-Index - 55

eISSN - 1178-203X

pISSN - 1176-6336

DOI - 10.2147/tcrm.s17413

Subject(s) - medicine , cephalosporin , pneumonia , streptococcus pneumoniae , bacterial pneumonia , staphylococcus aureus , antibiotics , community acquired pneumonia , intensive care medicine , methicillin resistant staphylococcus aureus , microbiology and biotechnology , bacteria , genetics , biology

Ceftaroline is a novel broad-spectrum cephalosporin β-lactam antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA) as well as multidrug-resistant Streptococcus pneumoniae among other routine Gram positive and Gram negative organisms. It has been approved by the US Food and Drug Administration for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections (ABSSSIs). Ceftaroline is approved for treatment of ABSSSI due to MRSA, however currently there are no data for pneumonia due to MRSA in humans. Herein we review the major clinical trials as well as ceftaroline microbiology, pharmacokinetics, and safety, followed by a look at further directions for investigation of this new agent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research